Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2000

01-12-1999 | Paper Report

IgA anti-?2-glycoprotein I antibodies

Author: Carrock Sewell

Published in: Arthritis Research & Therapy | Issue 1/2000

Login to get access

Excerpt

The anti phospholipid syndrome (APS) is characterised by clinical manifestations of thromboembolic phenomena, intra-uterine fetal loss and thrombocytopenia. APS is also associated with anti-phospholipid antibodies, which are autoantibodies directed against a modified ?2-glycoprotein I (?2-GPI). The modified structure is a result of interaction with anionic phospholipids. Although IgG, and to some extent IgM anti phospholipid antibodies are recognised as being of diagnostic significance, the role of IgA autoantibodies is not clear. This study examined the role of IgG, IgM and IgA isotype anti-?2-GPI in APS. To evaluate the prevalance of IgG, IgA and IgM anti-?2-GPI antibodies in APS, and to establish the clinical significance of IgA type antibodies compared with other isotypes. …
Literature
1.
go back to reference Lakos G, Kiss E, Regeczy N: Isotype distribution and clinical relevance of anti-?2-glycoprotein I (?2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999, 117: 574-579.PubMedPubMedCentralCrossRef Lakos G, Kiss E, Regeczy N: Isotype distribution and clinical relevance of anti-?2-glycoprotein I (?2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999, 117: 574-579.PubMedPubMedCentralCrossRef
Metadata
Title
IgA anti-?2-glycoprotein I antibodies
Author
Carrock Sewell
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar-1999-66741

Other articles of this Issue 1/2000

Arthritis Research & Therapy 1/2000 Go to the issue

Paper Report

OX40/OX40L in RA

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine